Barron's Weekend Stock Picks: Chevron, Apple, Disney And Insulet's Stock Increase

Benzinga reviews this weekend's top stories covered by Barron's. Here are the articles investors need to read.

In "Buy Chevron Stock. It’s Been Punished Enough for Earnings and the Hess Deal," Andrew Bary writes that Chevron Corporation's stock CVX is down 17% in 2023, but its long-term potential and attractive valuation may provide a 4.5% dividend yield despite asset management challenges.

In "Apple Isn’t Growing. That May Not Be the Biggest Issue for the Stock," Eric J. Savitz says that Apple Inc's AAPL

recent quarterly report revealed a lack of growth with declining revenue and that questions arise about the company's ability to grow compared to other tech giants, which, in turn, could potentially affect Apple's stock valuation.

In "Disney Faces Peltz’s Second Assault," Carleton English writes that, as Walt Disney Co DIS reports Q4 earnings, it faces a renewed activist campaign led by Trian Fund Management, with former Marvel executive Ike Perlmutter supporting Trian's effort to gain seats on Disney's board.

In "Bill Stock Tumbles 30%. Analyst Cites ‘Souring Macro’ for Downgrade," Tae Kim notes that KeyBanc Capital Markets downgraded Bill Holdings Inc BILL after a disappointing Q1 outlook, leading to a 32% share price drop.

In "Insulet Stock Rallies on Revenue Boost. It’s a ‘Misunderstood Growth Name,'" Emily Dattilo writes that medical device company Insulet Corporation PODD saw its stock rise by 15% as the company raised its revenue outlook following strong Q3 earnings and an increased full-year revenue growth projection.

Read Next: Berkshire Hathaway's Operating Earnings Soar Over 40% In Q3 — Did Buffet's Empire Defy Economic Headwinds This Season?

This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Photo: Shutterstock